Quadrature Capital’s Rapport Therapeutics RAPP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$951K Buy
28,318
+21,959
+345% +$948K 0.01% 1074
2026
Q2
$265K Buy
+6,359
New +$234K ﹤0.01% 1254
2026
Q1
– Sell
-8,837
Closed -$268K – 1955
2025
Q4
$268K Buy
+8,837
New +$245K ﹤0.01% 883

Other funds holding RAPP

Quadrature Capital's RAPP Position: Q3 2026 in Review

Quadrature Capital increased its Rapport Therapeutics (RAPP) stake by 345% in Q3 2026, buying an estimated $948K and bringing the position to 28,318 shares worth $951K. The position accounts for 0.01% of the portfolio, ranked #1074.

Quadrature Capital first reported a position in RAPP in Q4 2025 and has held it in 3 quarters since. 167 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Quadrature Capital held 28,318 shares of Rapport Therapeutics worth $951K as of Q3 2026.
  • Quadrature Capital bought 21,959 Rapport Therapeutics shares in Q3 2026, an estimated $948K.
  • Rapport Therapeutics made up 0.01% of Quadrature Capital's portfolio in Q3 2026, its #1074 holding.
  • Quadrature Capital first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 167 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Quadrature Capital's 13F filing for Q3 2026, filed 13 Nov 2026.